간헐성 파행 시장 보고서(2025년)
Intermittent Claudication Global Market Report 2025
상품코드 : 1730913
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

간헐성 파행 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.2%로 성장할 전망이며, 173억 9,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장은 당뇨병 유병률 증가, 비만율 상승, 심혈관 질환 유병률 증가, 알코올 및 담배 소비량 증가, 헬스케어 지출 증가와 같은 요인에 기인하고 있습니다. 예측 기간 주요 동향으로는 PAD 진단의 진보, 웨어러블 디바이스 통합, 맞춤형 의료의 도입, 약제 용출 스텐트로의 시프트, 줄기세포 치료의 진보 등을 들 수 있습니다.

말초동맥질환(PAD)의 이환율 상승은 향후 수년간 간헐성 점진 시장의 성장을 견인할 것으로 예측됩니다. PAD는 동맥이 좁아지면서 손발의 혈류가 감소해 통증이나 저림 등의 합병증을 일으키는 순환기계 질환입니다. PAD 증례의 증가는 고령화, 당뇨병, 흡연, 고혈압, 비만, 앉기 쉬운 라이프 스타일 등의 요인과 관련되어 있습니다. PAD는 운동 시 다리 근육으로의 혈류를 제한하여 산소 부족으로 인한 통증과 경련을 일으킵니다. 2023년 6월에 발행된 미국심장협회 잡지에 따르면 PAD는 미국에서 700만-1,200만 명, 세계에서 2억 명에게 영향을 미치고 있습니다. 이 PAD의 유병률 증가가 간헐성 파행 시장의 확대를 촉진하고 있습니다.

간헐성 파행 시장의 기업은 말초 동맥 질환 및 간헐성 파행 환자의 치료 성적을 개선하기 위해 RIPK1 억제제와 같은 고급 약물 요법의 개발에 주력하고 있습니다. 이러한 치료제는 혈류를 촉진하고 염증을 억제하며 질병 진행을 예방하는 것을 목표로 합니다. RIPK1 억제제는 RIPK1 키나아제 활성을 억제하는 표적 약물이며 염증과 세포 사멸을 억제합니다. 2022년 8월, 중국에 본사를 두고 있는 생명공학 기업인 GenFleet사는 간헐성 파행을 이용한 PAD의 신규 치료제 GFH312의 2상 임상시험을 실시하는 승인을 미국 식품의약국(FDA)으로부터 취득했습니다. 이 무작위화, 이중 맹검, 위약 대조 시험은 15개의 연구센터에서 실시됩니다. GFH312는 RIPK1 억제제이며 전임상시험에서 동물 모델의 염증을 억제함으로써 유망한 결과를 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Intermittent claudication is a condition marked by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is usually caused by peripheral artery disease (PAD), which occurs when narrowed or blocked arteries restrict blood flow to the muscles. The pain is typically due to a lack of oxygen (ischemia) in the affected muscles.

The primary treatments for intermittent claudication include medication therapies and revascularization procedures. Medication therapies involve the use of drugs to relieve symptoms, improve blood flow, reduce pain, and prevent complications related to poor circulation. These medications are administered through various methods, such as parenteral, oral, and other routes, and are used in settings such as hospitals, clinics, and home healthcare. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intermittent claudication market research report is one of a series of new reports from The Business Research Company that provides intermittent claudication market statistics, including the intermittent claudication industry's global market size, regional shares, competitors with a intermittent claudication market share, detailed intermittent claudication market segments, market trends and opportunities, and any further data you may need to thrive in the intermittent claudication industry. This intermittent claudication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intermittent claudication market size has grown strongly in recent years. It will grow from $12.81 billion in 2024 to $13.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rise in peripheral artery disease, increased awareness of vascular diseases, growth in the geriatric population, higher diagnosis rates, and an increase in healthcare spending.

The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of diabetes, rising obesity rates, growing prevalence of cardiovascular diseases, higher alcohol and tobacco consumption, and increasing healthcare spending. Key trends in the forecast period include advancements in PAD diagnostics, the integration of wearable devices, the incorporation of personalized medicine, a shift toward drug-eluting stents, and progress in stem cell therapy.

The rising incidence of peripheral artery disease (PAD) is expected to drive the growth of the intermittent claudication market in the coming years. PAD is a circulatory condition where narrowed arteries reduce blood flow to the limbs, causing pain, numbness, and other complications. The increasing number of PAD cases is linked to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. PAD leads to intermittent claudication by limiting blood flow to the leg muscles during physical activity, resulting in pain and cramping due to a lack of oxygen. According to the American Heart Association Journals, published in June 2023, PAD affects 7 to 12 million people in the U.S. and 200 million people worldwide. This growing prevalence of PAD is driving the expansion of the intermittent claudication market.

Companies in the intermittent claudication market are focusing on developing advanced medication therapies, such as RIPK1 inhibitors, to improve treatment outcomes for patients with peripheral artery disease and intermittent claudication. These therapies aim to enhance blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors are targeted drugs that block RIPK1 kinase activity, which helps reduce inflammation and cell death. In August 2022, GenFleet, a biotechnology company based in China, received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial for GFH312, a new treatment for PAD with intermittent claudication. This randomized, double-blind, placebo-controlled study will take place at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promising results in preclinical studies by reducing inflammation in animal models.

In April 2023, Abbott Laboratories, a healthcare company based in the U.S., acquired Cardiovascular Systems Inc. for $890 million. This acquisition is aimed at expanding Abbott's vascular device portfolio by incorporating Cardiovascular Systems Inc.'s advanced technologies for treating peripheral and coronary artery disease. The acquisition strengthens Abbott's position in the cardiovascular market and improves patient care with innovative, minimally invasive solutions. Cardiovascular Systems Inc. is a U.S.-based medical device company known for its innovative treatments for peripheral artery disease, including intermittent claudication.

Major players in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, and Pharmacompass.

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intermittent claudication report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intermittent claudication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intermittent claudication market includes revenues earned by entities by providing services such as non-invasive tests, angioplasty, stent placement, supervised exercise therapy, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The intermittent claudication market also consists of sales of antiplatelet agents, statins, vasodilators, and special socks or stockings. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intermittent Claudication Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intermittent claudication market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for intermittent claudication ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intermittent claudication market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Intermittent Claudication Market Characteristics

3. Intermittent Claudication Market Trends And Strategies

4. Intermittent Claudication Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intermittent Claudication Growth Analysis And Strategic Analysis Framework

6. Intermittent Claudication Market Segmentation

7. Intermittent Claudication Market Regional And Country Analysis

8. Asia-Pacific Intermittent Claudication Market

9. China Intermittent Claudication Market

10. India Intermittent Claudication Market

11. Japan Intermittent Claudication Market

12. Australia Intermittent Claudication Market

13. Indonesia Intermittent Claudication Market

14. South Korea Intermittent Claudication Market

15. Western Europe Intermittent Claudication Market

16. UK Intermittent Claudication Market

17. Germany Intermittent Claudication Market

18. France Intermittent Claudication Market

19. Italy Intermittent Claudication Market

20. Spain Intermittent Claudication Market

21. Eastern Europe Intermittent Claudication Market

22. Russia Intermittent Claudication Market

23. North America Intermittent Claudication Market

24. USA Intermittent Claudication Market

25. Canada Intermittent Claudication Market

26. South America Intermittent Claudication Market

27. Brazil Intermittent Claudication Market

28. Middle East Intermittent Claudication Market

29. Africa Intermittent Claudication Market

30. Intermittent Claudication Market Competitive Landscape And Company Profiles

31. Intermittent Claudication Market Other Major And Innovative Companies

32. Global Intermittent Claudication Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intermittent Claudication Market

34. Recent Developments In The Intermittent Claudication Market

35. Intermittent Claudication Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기